The evolution of immunosuppression with FK506 in pediatric living-related liver transplantation

Transplantation

Volumn 61, Issue 2, 1996, Pages 247-252

  Inomata, Yukihiro ^a   Tanaka, Koichi ^a   Egawa, Hiroto ^a   Uemoto, Shinji ^a   Ozaki, Nobuhiro ^a   Okajima, Hideaki ^a   Satomura, Kazunari ^a   Kiuchi, Tetsuya ^a   Yamaoka, Yoshio ^a   Hashida, Tohru ^a  

^a KYOTO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

TACROLIMUS;

ARTICLE; CHILD; CLINICAL TRIAL; DIABETES MELLITUS; DRUG EFFECT; DRUG SAFETY; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; LIVER FAILURE; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; NEPHROTOXICITY; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL;

ADMINISTRATION, ORAL; ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFANT; INJECTIONS, INTRAVENOUS; LIVER TRANSPLANTATION; MALE; RETROSPECTIVE STUDIES; SURVIVAL ANALYSIS; TACROLIMUS;

EID: 9044242096     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199601270-00015     Document Type: Article

References (30)

1. Kino T, Hatanaka H, Hashimoto H, et al. FK506, a novel immunosuppressant isolated from a Streptomyces: I. Fermentation, isolation, and physiochemical and biological characteristics. J Antibiot 1987a; 40: 1249.
2. Kino T, Hatanaka H, Miyata S, et al. FK506 a novel immunosuppressant isolated from a Streptomyces: II. Immunosuppressive effect of FK506 in vitro. J. Antibiot 1987b; 40: 1256.
3. Starzl TE, Todo S, Fung J, et al. FK506 for human liver, kidney, and pancreas transplantation. Lancet 1989; 2: 1000.
4. The US multicenter FK506 Liver Study Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110.
5. European FK506 Multicenter Liver Study Group. Randomised trial comparing tacrolimus (FK506) and cyclosporine in prevention of liver allograft rejection. Lancet 1994; 344:
6. Tzakis AG, Reyes J, Todo S, et al. FK506 versus cyclosporine in pediatric liver transplantation. Transplantation Proc 1991; 23: 3020.
7. Muller AR, Platz KP, Bechstein WO, et al. Neurotoxicity after orthotopic liver transplantation: a comparison between cyclosporine and FK506. Transplantation 1994; 58: 156.
8. Plat KP, Muller AR, Blumhardt G, et al. Nephrotoxicity following orthotopic liver transplantation, a comparison between cyclosporine and FK506. Transplantation 1994; 58: 156.
9. Uemoto S, Tanaka K, Honda K, et al. Experience with FK506 in living related liver transplantation. Transplantation 1993; 55: 288.
10. Tanaka K, Uemoto S, Tokunaga Y, et al. Surgical techniques and innovation in living related liver transplantation. Ann Surg 1993; 217: 82.
11. Yamaoka Y, Ozawa K, Tanaka A, et al. New devices for harvesting a hepatic graft from a living donor. Transplantation 1991; 52: 157.
12. Hashida T, Ikenishi M, Toraguchi M, et al. Therapeutic drug monitoring of tacrolimus using microparticle enzyme immunoassay method. J TDM Res 1994; 11: 18.
13. Starzl TE, Demetris AJ. Liver transplantation. Chicago, IL: Year Book, Inc. 1990: 1.
14. Yasuhara M, Hashida T, Toraguchi Y, et al. Pharmacokinetics and Pharmacodynamics of FK506 in pediatric patients: living-related donor liver transplantation. Transplant Proc 1995; 27: 1108.
15. Backman L, Nicaar M, Levy M, et al. FK506 trough levels in whole blood and plasma in liver transplant recipients. Correlation with clinical events and side effects. Transplantation 1994; 57: 519.
16. Sewing KFR. Pharmacokinetics, dosing principles, and blood level monitoring of FK506. Transplant Proc 1994; 26: 3267.
17. Todo S, Fung JJ, Starzl TE, et al. Single-center experience with primary orthotopic liver transplantation with FK506 immunosuppression. Ann Surg 1994; 220: 297.
18. Tzakis AG, Reyes J, Todo S, et al. Two year experience with FK506 in pediatric patients. Transplantation Proc 1991; 23: 2763.
19. Busuttil R, Sahked A, Millis JM, et al. One thousand liver transplants: the lessons learned. Ann Surg 1994; 219: 490.
20. Singh N, Mieles L, Yu VL, et al. Decreased incidence of viral infections in liver transplantation recipients: possible effects of FK506? Dig Dis Sci 1994; 39: 15.
21. Reding R, Wallemacq PE, Lamy ME, et al. Reversal of severe FK506 side effects by conversion from cyclosporine to FK506 for salvage of immunocompromised pediatric liver allografts. Transplantation 1994; 57: 93.
22. Mor E, Schwersenz A, Sheiner PA, et al. Reverssal of FK506 side effects by conversion to cyclosporine-based immunosuppression. Transplantation 1994; 58: 380.
23. Mor E, Schwersenz A, Sheiner PA, et al. Reversal of gastrointestinal toxicity associated with long-term FK506 immunosuppression by conversion to cyclosporine in liver transplant recipients. Transplantation. 1994; 57: 1130.
24. Steinmuller DR. FK506 and organ transplantation; Clinical organ transplantation studies. Austin, TX: Landes 1994: 19.
25. Li PKT, Nicholis MG, Lai KN, et al. The complications of newer transplant antirejection drugs: treatment with cyclosporine A, OKT3, and FK506. Adverse Drug React Acute Poisoning Rev 1990; 9: 123.
26. McCauley J, Fung JJ, Jain A, et al. The effects of FK 506 on renal function after liver transplantation. Transplant Proc 1990; 22: 17.
27. Winkler M, Jost U, Ringe B, et al. Association of elevated FK506 plasma levels with nephrotoxicity in liver-grafted patients. Transplant Proc 1991; 23: 3155.
28. Fung JJ, Alessiani M, Abu-Elmagd K, et al. Adverse effects associated with the use of FK506. Transplant Proc 1991; 23: 3105.
29. Ab-Elmagd K, Fung JJ, Alessiani M, et al. The effect of graft function on FK506 plasma levels, dosages, and renal function, with particular reference to the liver. Transplantation 1991; 52: 71.
30. Rmos HC, Reyes J, Ab-Elmagd, K et al. Weaning of immunosuppression in long term liver transplant recipients. Transplantation 1995; 59: 212.